HRP20110759T1 - Novi derivati imidazolona, njihovo dobivanje u svojstvu lijekova, njihovi farmaceutski pripravci i njihova upotreba u svojstvu inhibitora protein-kinaza, osobito cdc7 - Google Patents
Novi derivati imidazolona, njihovo dobivanje u svojstvu lijekova, njihovi farmaceutski pripravci i njihova upotreba u svojstvu inhibitora protein-kinaza, osobito cdc7 Download PDFInfo
- Publication number
- HRP20110759T1 HRP20110759T1 HR20110759T HRP20110759T HRP20110759T1 HR P20110759 T1 HRP20110759 T1 HR P20110759T1 HR 20110759 T HR20110759 T HR 20110759T HR P20110759 T HRP20110759 T HR P20110759T HR P20110759 T1 HRP20110759 T1 HR P20110759T1
- Authority
- HR
- Croatia
- Prior art keywords
- radical
- alkyl
- radicals
- optionally substituted
- hydrogen atom
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims 5
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical class O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 title 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 101150065030 cdc7 gene Proteins 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- -1 cycloalkyl radical Chemical class 0.000 claims abstract 143
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 70
- 125000000217 alkyl group Chemical group 0.000 claims abstract 69
- 150000003254 radicals Chemical class 0.000 claims abstract 58
- 125000005843 halogen group Chemical group 0.000 claims abstract 48
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 33
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 28
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 26
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 26
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 24
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 20
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims abstract 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 13
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract 13
- 125000003118 aryl group Chemical group 0.000 claims abstract 12
- 229910052736 halogen Inorganic materials 0.000 claims abstract 12
- 150000002367 halogens Chemical class 0.000 claims abstract 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 8
- 150000005840 aryl radicals Chemical group 0.000 claims abstract 7
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims abstract 7
- 125000005842 heteroatom Chemical group 0.000 claims abstract 4
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 4
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 4
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract 3
- 125000003709 fluoroalkyl group Chemical group 0.000 claims abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 16
- 150000007529 inorganic bases Chemical class 0.000 claims 15
- 150000007522 mineralic acids Chemical class 0.000 claims 15
- 150000007524 organic acids Chemical class 0.000 claims 15
- 150000007530 organic bases Chemical class 0.000 claims 15
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 229940127554 medical product Drugs 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000005936 piperidyl group Chemical group 0.000 claims 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 4
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 2
- 210000003584 mesangial cell Anatomy 0.000 claims 2
- 235000005985 organic acids Nutrition 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000002231 Muscle Neoplasms Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000003725 azepanyl group Chemical group 0.000 claims 1
- 125000002785 azepinyl group Chemical group 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 201000002077 muscle cancer Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 210000002229 urogenital system Anatomy 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0608924A FR2907120B1 (fr) | 2006-10-12 | 2006-10-12 | Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7 |
| PCT/FR2007/001651 WO2008046982A2 (fr) | 2006-10-12 | 2007-10-10 | Nouveaux derives imidazolones, leur preparation a titre de medicaments, compositions pharmaceutiques, utilisation comme inhibiteurs de proteines kinases notamment cdc7 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110759T1 true HRP20110759T1 (hr) | 2011-11-30 |
Family
ID=37964098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110759T HRP20110759T1 (hr) | 2006-10-12 | 2011-10-19 | Novi derivati imidazolona, njihovo dobivanje u svojstvu lijekova, njihovi farmaceutski pripravci i njihova upotreba u svojstvu inhibitora protein-kinaza, osobito cdc7 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8314121B2 (de) |
| EP (1) | EP2094699B1 (de) |
| JP (1) | JP2010505922A (de) |
| KR (1) | KR101552361B1 (de) |
| CN (1) | CN101522678A (de) |
| AR (1) | AR063249A1 (de) |
| AT (1) | ATE517105T1 (de) |
| AU (1) | AU2007311833B2 (de) |
| BR (1) | BRPI0719790A2 (de) |
| CA (1) | CA2660166C (de) |
| CL (1) | CL2007002934A1 (de) |
| CO (1) | CO6160310A2 (de) |
| CY (1) | CY1112066T1 (de) |
| DK (1) | DK2094699T3 (de) |
| EA (1) | EA018496B1 (de) |
| ES (1) | ES2370049T3 (de) |
| FR (1) | FR2907120B1 (de) |
| HR (1) | HRP20110759T1 (de) |
| IL (1) | IL197452A (de) |
| MA (1) | MA30877B1 (de) |
| MX (1) | MX2009003283A (de) |
| NO (1) | NO20091486L (de) |
| PL (1) | PL2094699T3 (de) |
| PT (1) | PT2094699E (de) |
| RS (1) | RS51985B (de) |
| SI (1) | SI2094699T1 (de) |
| TW (1) | TW200821310A (de) |
| UY (1) | UY30642A1 (de) |
| WO (1) | WO2008046982A2 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120024619A (ko) | 2009-04-20 | 2012-03-14 | 에스비아이 바이오테크 가부시키가이샤 | 티아졸리디논 유도체 |
| JP2012533553A (ja) * | 2009-07-15 | 2012-12-27 | アボット・ラボラトリーズ | ピロロピリジン系キナーゼ阻害薬 |
| RU2607453C2 (ru) * | 2009-12-04 | 2017-01-10 | Сенхва Байосайенсиз, Инк. | Пиразолопиримидины и родственные гетероциклы как ск2 ингибиторы |
| EP2560971B1 (de) | 2010-04-19 | 2014-04-09 | Abbvie Inc. | Pyrrolopyridine als inhibitoren von kinasen |
| KR101964479B1 (ko) * | 2011-03-31 | 2019-04-01 | 카나 바이오사이언스, 인코포레이션 | 신규 푸라논 유도체 |
| US9974795B2 (en) | 2014-01-31 | 2018-05-22 | Carna Biosciences, Inc. | Anticancer agent composition |
| GB201807147D0 (en) | 2018-05-01 | 2018-06-13 | Oncologica Uk Ltd | Therapeutic combination |
| KR102491260B1 (ko) * | 2019-12-26 | 2023-01-27 | 연세대학교 산학협력단 | 피롤리딘 유도체 및 이를 포함하는 베타-아밀로이드 또는 타우 단백질 관련 질병의 예방 또는 치료용 약학 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6335342B1 (en) | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| EP2295433A3 (de) | 2003-03-06 | 2011-07-06 | Eisai R&D Management Co., Ltd. | JNK Inhibitoren |
| DE602004014163D1 (de) * | 2003-08-08 | 2008-07-10 | Pfizer Italia Srl | Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken |
| JP5019612B2 (ja) | 2004-04-02 | 2012-09-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｒｏｃｋの阻害剤として有用なアザインドールおよび他のプロテインキナーゼ |
| DE602005005211T2 (de) * | 2004-10-14 | 2009-03-19 | F. Hoffmann-La Roche Ag | Neue azaindol-thiazolinone als krebsmittel |
| US7371862B2 (en) * | 2005-11-11 | 2008-05-13 | Pfizer Italia S.R.L. | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
-
2006
- 2006-10-12 FR FR0608924A patent/FR2907120B1/fr not_active Expired - Fee Related
-
2007
- 2007-10-10 RS RS20110456A patent/RS51985B/en unknown
- 2007-10-10 SI SI200730750T patent/SI2094699T1/sl unknown
- 2007-10-10 KR KR1020097007392A patent/KR101552361B1/ko not_active IP Right Cessation
- 2007-10-10 AU AU2007311833A patent/AU2007311833B2/en not_active Ceased
- 2007-10-10 JP JP2009531874A patent/JP2010505922A/ja not_active Revoked
- 2007-10-10 EA EA200970364A patent/EA018496B1/ru not_active IP Right Cessation
- 2007-10-10 CN CNA2007800378600A patent/CN101522678A/zh active Pending
- 2007-10-10 BR BRPI0719790-0A2A patent/BRPI0719790A2/pt not_active IP Right Cessation
- 2007-10-10 ES ES07858418T patent/ES2370049T3/es active Active
- 2007-10-10 AT AT07858418T patent/ATE517105T1/de active
- 2007-10-10 PL PL07858418T patent/PL2094699T3/pl unknown
- 2007-10-10 PT PT07858418T patent/PT2094699E/pt unknown
- 2007-10-10 CA CA2660166A patent/CA2660166C/fr not_active Expired - Fee Related
- 2007-10-10 DK DK07858418.2T patent/DK2094699T3/da active
- 2007-10-10 EP EP07858418A patent/EP2094699B1/de active Active
- 2007-10-10 WO PCT/FR2007/001651 patent/WO2008046982A2/fr active Application Filing
- 2007-10-10 MX MX2009003283A patent/MX2009003283A/es active IP Right Grant
- 2007-10-11 CL CL200702934A patent/CL2007002934A1/es unknown
- 2007-10-11 AR ARP070104500A patent/AR063249A1/es unknown
- 2007-10-12 UY UY30642A patent/UY30642A1/es not_active Application Discontinuation
- 2007-10-12 TW TW096138357A patent/TW200821310A/zh unknown
-
2009
- 2009-03-05 IL IL197452A patent/IL197452A/en not_active IP Right Cessation
- 2009-03-31 US US12/415,391 patent/US8314121B2/en not_active Expired - Fee Related
- 2009-04-08 CO CO09036259A patent/CO6160310A2/es unknown
- 2009-04-16 NO NO20091486A patent/NO20091486L/no not_active Application Discontinuation
- 2009-05-08 MA MA31856A patent/MA30877B1/fr unknown
-
2011
- 2011-10-19 HR HR20110759T patent/HRP20110759T1/hr unknown
- 2011-10-20 CY CY20111100996T patent/CY1112066T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110759T1 (hr) | Novi derivati imidazolona, njihovo dobivanje u svojstvu lijekova, njihovi farmaceutski pripravci i njihova upotreba u svojstvu inhibitora protein-kinaza, osobito cdc7 | |
| JP6732855B2 (ja) | 疼痛を治療するためのアザインダゾールまたはジアザインダゾール型の誘導体 | |
| JP6181862B2 (ja) | ピラゾロピロリジン誘導体および疾患の処置におけるその使用 | |
| JP5931926B2 (ja) | 医薬としてのアザインダゾールまたはジアザインダゾール型の誘導体 | |
| JP6695353B2 (ja) | Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体 | |
| HRP20121069T1 (hr) | Supstituirani derivati amida kao inhibitori protein kinaze | |
| NZ591712A (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
| RU2672910C2 (ru) | Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы | |
| El-Nassan | Recent progress in the identification of BRAF inhibitors as anti-cancer agents | |
| HRP20090380T1 (hr) | SUPSTITUIRANI 1H-PIROLO[3,2-b, 3,2-c, i 2,3-c]PIRIDIN-2-KARBOKSAMIDI I SRODNI ANALOZI KAO INHIBITORI KAZEIN-KINAZE Iε | |
| HRP20130106T1 (hr) | Imidazotriazini i imidazopirimidini kao inhibitori kinaze | |
| RU2017145026A (ru) | Соединение, ингибирующее brk | |
| JP2014139226A5 (de) | ||
| CN105209460A (zh) | 作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物 | |
| RU2014115476A (ru) | Производные пиразоло[4, 3-с]птридина в качестве ингибиторов киназ | |
| WO2007079999A2 (de) | Pyridopyrazin-derivate und deren verwendung als modulatoren der signaltransduktionswege | |
| NZ613219A (en) | Heterocyclic containing entities, compositions and methods | |
| JP2015518895A (ja) | Ｅｇｆｒ活性を調節するための化合物および組成物 | |
| EA201101566A1 (ru) | Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ | |
| US20210000825A1 (en) | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | |
| HRP20140786T1 (hr) | DERIVATI 6,7,8,9-TETRAHIDROPIRIMIDO[1,2-a]PIRIMIDIN-4-ONA, NJIHOVO DOBIVANJE I NJIHOVA FARMACEUTSKA UPOTREBA | |
| AR042148A1 (es) | Derivados de indazol como antagonistas de crf | |
| RU2011125314A (ru) | Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в | |
| RU2009103300A (ru) | Производные 2-бензоилимидазопиридинов, их получение и их применение в терапии | |
| HRP20110550T1 (hr) | Derivati 7-alkinil-1,8-naftiridinona, njihovo dobivanje i njihova upotreba u terapiji |